Business Description
Gensight Biologics SA
NAICS : 325412
SIC : 2834
ISIN : FR0013183985
Compare
Compare
Traded in other countries / regions
SIGHT.FranceG49N.Germany0RIM.UKGSGTF.USA IPO Date
2016-07-13Description
Gensight Biologics SA is a clinical-stage biotechnology group discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system. The company's pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence, and Optogenetics, to help preserve or restore vision in patients suffering from severe degenerative retinal diseases. The group's focus is on ophthalmology where it develops product candidates to restore eyesight to patients suffering from retinal diseases. The product candidate, LUMEVOQ, was developed using the MTS technology platform and is designed to treat LHON by restoring the function of retinal diseases resulting from mutations.
Financial Strength
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.4 | |||||
| Equity-to-Asset | -1.66 | |||||
| Debt-to-Equity | -0.7 | |||||
| Debt-to-EBITDA | -1.09 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -14.15 | |||||
| Beneish M-Score | -4.06 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -40.8 | |||||
| 3-Year EBITDA Growth Rate | 21.5 | |||||
| 3-Year EPS without NRI Growth Rate | 3.6 | |||||
| 3-Year FCF Growth Rate | -6.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate | -20.47 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 64.26 | |||||
| 9-Day RSI | 55.7 | |||||
| 14-Day RSI | 51.34 | |||||
| 6-1 Month Momentum % | -22.11 | |||||
| 12-1 Month Momentum % | -41.95 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.77 | |||||
| Quick Ratio | 0.77 | |||||
| Cash Ratio | 0.41 | |||||
| Days Sales Outstanding | 11.35 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -16.7 | |||||
| Shareholder Yield % | -56.76 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -2487.94 | |||||
| Net Margin % | -2500.75 | |||||
| FCF Margin % | -1965.3 | |||||
| ROA % | -147.66 | |||||
| ROIC % | -118.1 | |||||
| ROC (Joel Greenblatt) % | -1095.58 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 43.64 | |||||
| EV-to-EBIT | -2.68 | |||||
| EV-to-EBITDA | -3.03 | |||||
| EV-to-Revenue | 60.16 | |||||
| EV-to-FCF | -2.89 | |||||
| Earnings Yield (Greenblatt) % | -37.37 | |||||
| FCF Yield % | -41.77 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Gensight Biologics SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.804 | ||
| EPS (TTM) (€) | -0.35 | ||
| Beta | 0.43 | ||
| Volatility % | 39.91 | ||
| 14-Day RSI | 51.34 | ||
| 14-Day ATR (€) | 0.024704 | ||
| 20-Day SMA (€) | 0.31735 | ||
| 12-1 Month Momentum % | -41.95 | ||
| 52-Week Range (€) | 0.28 - 0.598 | ||
| Shares Outstanding (Mil) | 115.16 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Gensight Biologics SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Gensight Biologics SA Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Gensight Biologics SA Frequently Asked Questions
What is Gensight Biologics SA(XPAR:SIGHT)'s stock price today?
The current price of XPAR:SIGHT is €0.33. The 52 week high of XPAR:SIGHT is €0.60 and 52 week low is €0.28.
When is next earnings date of Gensight Biologics SA(XPAR:SIGHT)?
The next earnings date of Gensight Biologics SA(XPAR:SIGHT) is .
Does Gensight Biologics SA(XPAR:SIGHT) pay dividends? If so, how much?
Gensight Biologics SA(XPAR:SIGHT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers